Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products

The development of nanotechnology-enabled health products offers innovative therapeutic and diagnostic opportunities to address medical needs. At the moment, no specific regulatory framework exists for such products since they can be covered by the existing frameworks for medicinal products and medi...

Full description

Bibliographic Details
Main Authors: Blanka Halamoda-Kenzaoui, Helen Box, Merel van Elk, Sandra Gaitan, Robert E. Geertsma, Eusebio Gainza Lafuente, Andrew Owen, Angel del Pozo, Matthias Roesslein, Susanne Bremer-Hoffmann
Format: Article
Language:English
Published: Andover House Inc.
Series:Precision Nanomedicine
Online Access:http://prnano.scholasticahq.com/article/13521-launching-stakeholder-discussions-on-identified-regulatory-needs-for-nanotechnology-enabled-health-products.pdf
id doaj-9788e24d75bf47bbae2232a3bcf317d3
record_format Article
spelling doaj-9788e24d75bf47bbae2232a3bcf317d32020-11-25T03:53:23ZengAndover House Inc.Precision Nanomedicine2639-9431Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health productsBlanka Halamoda-KenzaouiHelen BoxMerel van ElkSandra GaitanRobert E. GeertsmaEusebio Gainza LafuenteAndrew OwenAngel del PozoMatthias RoessleinSusanne Bremer-HoffmannThe development of nanotechnology-enabled health products offers innovative therapeutic and diagnostic opportunities to address medical needs. At the moment, no specific regulatory framework exists for such products since they can be covered by the existing frameworks for medicinal products and medical devices. However, these frameworks do require additional guidance in order to fully cover the particularities of nanotechnology-enabled products. After a detailed analysis of regulatory guidance documents, standards and scientific publications originating mainly from Europe and the US, the European project “REFINE” has released a White Paper summarising the main needs in the field. The selection of the regulatory pathway, the identification of regulatory information needs as well as the availability of standardised testing methods are among the identified regulatory challenges. Furthermore, more guidance is needed on how the similarity of follow-on medicinal products can be demonstrated. In addition, challenges related to the classification and assessment of nanotechnology–enabled medical devices are presented. The project consortium is now collecting feedback on the identified challenges through a dedicated survey and published comments to this manuscript. The resulting discussions within the scientific community should help to understand how essential knowledge, methods, tools and approaches can be obtained with the aim to advance the regulatory science in the area of nanotechnology-enabled health products.http://prnano.scholasticahq.com/article/13521-launching-stakeholder-discussions-on-identified-regulatory-needs-for-nanotechnology-enabled-health-products.pdf
collection DOAJ
language English
format Article
sources DOAJ
author Blanka Halamoda-Kenzaoui
Helen Box
Merel van Elk
Sandra Gaitan
Robert E. Geertsma
Eusebio Gainza Lafuente
Andrew Owen
Angel del Pozo
Matthias Roesslein
Susanne Bremer-Hoffmann
spellingShingle Blanka Halamoda-Kenzaoui
Helen Box
Merel van Elk
Sandra Gaitan
Robert E. Geertsma
Eusebio Gainza Lafuente
Andrew Owen
Angel del Pozo
Matthias Roesslein
Susanne Bremer-Hoffmann
Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
Precision Nanomedicine
author_facet Blanka Halamoda-Kenzaoui
Helen Box
Merel van Elk
Sandra Gaitan
Robert E. Geertsma
Eusebio Gainza Lafuente
Andrew Owen
Angel del Pozo
Matthias Roesslein
Susanne Bremer-Hoffmann
author_sort Blanka Halamoda-Kenzaoui
title Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
title_short Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
title_full Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
title_fullStr Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
title_full_unstemmed Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
title_sort launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
publisher Andover House Inc.
series Precision Nanomedicine
issn 2639-9431
description The development of nanotechnology-enabled health products offers innovative therapeutic and diagnostic opportunities to address medical needs. At the moment, no specific regulatory framework exists for such products since they can be covered by the existing frameworks for medicinal products and medical devices. However, these frameworks do require additional guidance in order to fully cover the particularities of nanotechnology-enabled products. After a detailed analysis of regulatory guidance documents, standards and scientific publications originating mainly from Europe and the US, the European project “REFINE” has released a White Paper summarising the main needs in the field. The selection of the regulatory pathway, the identification of regulatory information needs as well as the availability of standardised testing methods are among the identified regulatory challenges. Furthermore, more guidance is needed on how the similarity of follow-on medicinal products can be demonstrated. In addition, challenges related to the classification and assessment of nanotechnology–enabled medical devices are presented. The project consortium is now collecting feedback on the identified challenges through a dedicated survey and published comments to this manuscript. The resulting discussions within the scientific community should help to understand how essential knowledge, methods, tools and approaches can be obtained with the aim to advance the regulatory science in the area of nanotechnology-enabled health products.
url http://prnano.scholasticahq.com/article/13521-launching-stakeholder-discussions-on-identified-regulatory-needs-for-nanotechnology-enabled-health-products.pdf
work_keys_str_mv AT blankahalamodakenzaoui launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT helenbox launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT merelvanelk launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT sandragaitan launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT robertegeertsma launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT eusebiogainzalafuente launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT andrewowen launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT angeldelpozo launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT matthiasroesslein launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
AT susannebremerhoffmann launchingstakeholderdiscussionsonidentifiedregulatoryneedsfornanotechnologyenabledhealthproducts
_version_ 1724478367481200640